Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review

Review

Abstract: Primary Central Nervous System Lymphoma (PCNSL) is a rare variant of Non-Hodgkin Lymphoma (NHL) repr

Palabras claves:

Bruton tyrosine kinase inhibitor, BTK, Ibrutinib, Lymphoma, PCNSL, Primary central nervous system lymphoma

Autores:

Albert T., Bhagat R., Bhandari S., Bucheli D.H., Gajurel B.P., Joshi U., Juan Fernando Ortíz, Khurana M., Licata S., Nepal G., Ojha R., Pudasainee P., Quiñonez J., Rehrig J.H., Ruxmohan S., Shing Y.K., Stien J.

Fuentes:

scopus